Nasal spray depression treatment on track for FDA approval

A ketamine-like drug for treatment-resistant depression was backed by a US Food and Drug Administration advisory committee on Tuesday. If it is then approved by the FDA, the drug -- called esketamine -- may provide a new option for patients with major depressive disorder who have tried at least two other antidepressants without success.

Leave a Reply